Stay updated on Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.

Latest updates to the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page
- Check7 days agoChange DetectedA new page revision, v3.3.4, was added and the previous revision, v3.3.3, was removed.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedAdded a Florida location under Locations and updated the page revision to v3.3.3. Removed the older Florida Locations entry and the HHS Vulnerability Disclosure link.SummaryDifference0.4%

- Check56 days agoChange DetectedRevision metadata updated from v3.2.0 to v3.3.2; no user-facing content changes observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedBranding and navigation updates add references to the Moffitt Cancer Center Clinical Trials website and related entities, along with helpful links; a government funding operating-status notice was removed.SummaryDifference0.6%

- Check78 days agoChange DetectedUpdated study record dates: Enrollment (Actual) 13 and Study Completion (Actual) 2025-08-21, plus Last Update Posted 2025-10-01. The rest of the study details appear unchanged.SummaryDifference0.3%

- Check107 days agoChange DetectedCore content and status/version information updated: old recruitment/status indicators removed; newer operating status notice and updated dates/revision added.SummaryDifference4%

Stay in the know with updates to Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.